How Sapu Indexed 28 Million PubMed Abstracts to Accelerate Cancer Research with Qdrant

Sapu, a biopharmaceutical company focused on developing nanomedicine treatments for hard-to-treat cancers, has leveraged Qdrant's vector search technology to efficiently index 28 million PubMed abstracts, thus significantly enhancing its research capabilities. Initially facing limitations with early vector search solutions, Sapu transitioned to Qdrant Cloud Premium to address stability issues and gain compliance certifications like SOC 2, which are essential for licensing its AI platform to other biotech firms. This move has allowed Sapu to conduct comprehensive searches across biomedical literature, leading to the publication of seven peer-reviewed research papers and facilitating broader internal and external collaborations, including a partnership with robotics company Techforce to integrate AI into lab workflows. The AI platform, which began as a command-line prototype, now supports various research functions, from document retrieval to SOP-aware chatbots, and is set to expand into robotics and edge deployments, underscoring the importance of rapid information retrieval in accelerating therapeutic advancements.